(Q41724479)

English

A phase II study of two cycles of high-dose chemotherapy with autologous stem cell support in patients with metastatic breast cancer who meet eligibility criteria for a single cycle

scientific article published on March 2000

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

A phase II study of two cycles of high-dose chemotherapy with autologous stem cell support in patients with metastatic breast cancer who meet eligibility criteria for a single cycle (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

metastatic breast cancer

1 reference

based on heuristic

inferred from title

eligibility criteria

1 reference

based on heuristic

inferred from title

author name string

Bashey A

1

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Corringham S

2

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Garrett J

3

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Lane TA

4

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Gilpin EA

5

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Corringham RE

6

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Law P

7

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Ho AD

8

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

language of work or name

0 references

publication date

1 March 2000

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

519-524

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1702172

0 references

Cancer statistics, 1997.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702172

21 January 2018

Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702172

21 January 2018

High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702172

21 January 2018

Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702172

21 January 2018

High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702172

21 January 2018

High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702172

21 January 2018

High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702172

21 January 2018

Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: the LMCE2 study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702172

21 January 2018

Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702172

21 January 2018

Tamoxifen modulation of cisplatin cytotoxicity in human malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702172

21 January 2018

Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702172

21 January 2018

Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702172

21 January 2018

High-dose sequential chemotherapy with stem cell support for non-metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702172

21 January 2018

Diverse prognosis in metastatic breast cancer: who should be offered alternative initial therapies?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702172

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702172

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702172

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I and pharmacokinetic study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702172

7 January 2021

based on heuristic

inferred from DOI database lookup

Potential strategies for improving the results of high-dose chemotherapy in patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702172

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple cycles of high-dose doxorubicin and cyclophosphamide with G-CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702172

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1702172

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41724479&oldid=1926293944"